A venture update reports that Kallyope became TriGemX after the Novo obesity deal, raising $94 million to pursue its migraine pipeline. The financing is framed as a way to support the restructured Phase 3 development efforts for a former Tanabe Pharma drug candidate. The headline detail is capital formation tied to stage progression—an indicator that early funding markets are still willing to back late-stage execution when clinical plans are clearly scoped. The rebrand also aims to reduce investor and partner confusion by consolidating attention on a single therapeutic area. For companies and investors, the report functions as a reminder that portfolio focus is increasingly valued in crowded neuro and metabolic categories. Overall, the move positions TriGemX to sustain trial activity and regulatory interactions through key Phase 3 milestones.